Oncolytics announces highlights from KOL on pelareorep data

Oncolytics (ONCY) Biotech hosted a key opinion leader webinar featuring leading physicians in the fields of oncology and immunotherapy discussing pelareorep’s robust clinical data and how it fits in the evolving treatment landscape for pancreatic and gastrointestinalcancers. The KOLs provided individual presentations and then participated in a roundtable Q&A discussion. A selection of key takeaways includes: The meaningful survival benefit demonstrated by pelareorep-based treatment combinations in first-line metastatic pancreatic ductal adenocarcinoma patients across randomized and single-arm clinical studies necessitates evaluating pelareorep in a registration-enabling study in 1L mPDAC. Immunotherapies have not yet been approved to treat mPDAC patients, illustrating an unmet need, which provides an opportunity for an immunologically active agent like pelareorep to deliver an impactful clinical benefit in this challenging indication. The combination of pelareorep and chemotherapy would be an appealing treatment option for 1L mPDAC patients, even with the presence of RAS inhibitors in the treatment paradigm. Translational data from multiple mPDAC and colorectal cancer clinical trials validate pelareorep’s mechanism of action, showing that it replicates in tumors, stimulates chemokine expression, and induces the expansion of tumor-infiltrating lymphocytes, which correlates with a reduction in tumor size.